Date: 2015-05-16
Type of information: Nomination
Compound:
Company: Complix (Belgium)
Therapeutic area: Autoimmune diseases - Cancer - Oncology
Type agreement: nomination
Action mechanism:
Disease:
Details: * On May 16, 2014, Complix announced that it has appointed Yvonne McGrath as Chief Scientific Officer (CSO). As CSO of Complix, Dr McGrath will be responsible for the use of the Company´s Alphabody platform to identify new drug candidates and take these forward into development, either internally or with partners. Dr Ignace Lasters, previously CSO and co-founder of Complix, will assume the role of Chief Technology Officer (CTO), and will be responsible for the further development and expansion of the Alphabody technology platform. Dr McGrath was most recently at Immunocore as Head of Development and before that as Head of Preclinical Development and CMC. In these positions, she successfully developed and executed the late preclinical and early clinical strategy for a novel platform technology, managed meetings with European and US regulatory authorities and led manufacturing and CMC strategy for a new biological entity targeting cancer. Dr McGrath’s previous experience includes being a Project Manager at the UK subsidiary of the German biotech company MediGene AG, and Senior Scientist at BioVex (now part of Amgen). She has a PhD from the University of Wales, College of Medicine.
Financial terms:
Latest news:
